We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 11.50 | 11.00 | 12.00 | 11.50 | 11.50 | 11.50 | 211,809 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -5.86M | -0.0063 | -18.25 | 106.7M |
Date | Subject | Author | Discuss |
---|---|---|---|
11/12/2024 22:09 | Log I haven’t been here 10 years so it’s not an issue for me. It’s simply the market cap v the potential. I just had a look and I can see it hit 50p plus briefly in 2012 but has spent most of its time lower down. As a comparison Angle is around Scancell’s share price but was £1.40 in 2021 with an all time high of around £1.70. The point being even with all the dilution, on the back of good data and deals Scancell can easily exceed it’s all time high by some way. The past is done, monotherapy re Scib now with 5 years plus exceptional PFS data. They have never had so much going on in combo therapies awaiting data, with 2 Glymabs licensed in the same period and more to come. In city terms there is no looking backwards, it’s the next trade that counts. | chilltime | |
11/12/2024 19:25 | I certainly wasn't referring to you domino. We all know who the clueless predictors of stock price have been over the years. Inane the worst of course followed by chilli ..MT and the like. Log-man you are completely correct to ignore recs. They only indicate 'herding'. The herd ALWAYS get it wrong (by definition). Contrarians are the winners Yes, it feels more secure to be in a big group....but the stock market is not like real life. If the majority view is on one side of the fence....the market move will be on the other. The market is a place of irony, and complete contradiction. Tykey....pouring himself a stiff bourbon. | 2tyke | |
11/12/2024 19:13 | Chilltime ,you seem a decent person who are respected here by the recs on here.Some on here know how the log speaks . I couldn't give a Ducking hoot about recs.Look at the share price and shares in issue now and over the last ten years absolute shambles. | thelogman | |
11/12/2024 17:43 | My 10p prediction is still the closest of you all. So there | dominoman | |
11/12/2024 15:32 | Inanaco gone fishing btw...bit chilly ! | 2tyke | |
11/12/2024 15:26 | So funny.. How the clowns who've called the share price incorrectly at EVERY SINGLE turn, now think that they know what the share price should do going forward...lol Lucky old Markingtime...his Bitcoin is soaring 😂 | 2tyke | |
11/12/2024 12:34 | What's up with you fragma ? You must have some kind of problem. I'm not trashing anything. And...I do actually know what I'm talking about with stock prices. There is NO evidence on here that you do, however. If you want to criticise....state what you disagree with and put your point of view. It's all about intellectual honesty...and you don't seem to have it dude ! | 2tyke | |
11/12/2024 10:14 | I see the resident troll is again putting in double time today?Oh, the bitterness over losing a couple of hundred quid .Accept it and get over it, no point wasting all day trashing a stock you don't own anymore. | fragma | |
11/12/2024 09:27 | But not necessarily 'now' | 2tyke | |
11/12/2024 09:20 | "There is ALWAYS a good opportunity to buy into a stock....ALWAYS."Now ain't that the truth. | ruckrover | |
11/12/2024 08:53 | Yes it would be nice willoicc. But a very long way to go yet. A newspaper piece wouldn't make any difference. It's all out there already. It's not a knowledge issue. Stock market traders don't want missed opportunity cost with money stagnating. They can always jump in here further down the line. A lot of PI's irrationally think that they 'must' be in a stock in case the BIG news drops. I'll tell you something now that is completely true. Even if a massive deal came in and the stock soared....it would still give up 2/3 of that gain shortly afterwards. There is ALWAYS a good opportunity to buy into a stock....ALWAYS. Missed opportunity however is missed opportunity. | 2tyke | |
11/12/2024 08:37 | It would help the share price if we got this article into the Daily Mail paper. Better still this headline from a previous DM story on Scancell in 2010 'Holy Grail' cancer vaccine that blasts tumours in weeks ... SMALL CAP IDEA: Scancell is becoming a key player in cancer immunotherapy By IAN LYALL AT PROACTIVE INVESTORS FOR THISISMONEY.CO.UK | marcusl2 | |
11/12/2024 08:28 | It is risky but the world needs this to work to destroy a very nasty, cruel disease. | willoicc | |
11/12/2024 08:20 | His maths is poor...lol The market cap of this company is actually around 110 million. Higher than many revenue generating biotechs. There is a lot of 'hope' premium already baked into this company pie. Especially considering on-going likely dilution. Hence the share price trajectory. Very risky area. Biotech fund usually the way to go for bigger investments. | 2tyke | |
11/12/2024 08:06 | They would have 90% fewer shares which is not even 1 time fewer. | willoicc | |
10/12/2024 22:17 | Ok so far this last raise for shares currently in issue is a 10% dilution. Some over the last year or two have seen dilution multiples of the shares in issue, 10, 20 fold and so on. In the case of Scancell further dilution will be determined by results and partnerships/deals on the back of interest /results. There is currently strong interest from multiple big companies, so we’ll have to wait and see. Comparing deals in the last 5 years for new immuno type approaches suggests the various platforms potentially carry a very high value. We can’t take the UK market over the last few years to be a fair indicator of the potential value. Examples have been given where pharma have paid up front $200m and more for PRE clinical indications in the oncology sector with billion dollar total milestones for new exciting targets. Scancell are not jostling for a position in their field, chasing a trend, they created and lead it, if the big names are excited by the new methods, then Scancell is pretty much the world leader. No high risk toxicity, and commercially complicated. Effective, safe, and easy to produce, that’s what they have mastered over many years. | chilltime | |
10/12/2024 21:48 | Only ever be 21 million Bitcoin 😉 | 2tyke | |
10/12/2024 21:30 | My point is chill, example 1 billion shares in issue company sold for 1 billion pounds we get 1 pound. 2 billion shares company sold for 1 billion we get 50 P. Dilution. | thelogman | |
10/12/2024 21:23 | No I don’t get your logic log. The dilution was just around 10%, about 1 bill currently in issue. If 100m were in issue it would £1.10 or so per share now, you wouldn’t be getting them at 11p and investors would have 10 times less shares. | chilltime | |
10/12/2024 17:49 | Chilltime typo. | thelogman | |
10/12/2024 17:48 | Childlike if you think shares in issue is a stupid point that's your opinion , My opinion is shares in issue is relevant in a buyout for obvious reasons.Well very obvious to me. | thelogman | |
10/12/2024 17:07 | A few more mug punters getting sucked in here...probably inane amongst them. New lows are likely a coming to a stock near you ! | 2tyke | |
10/12/2024 17:03 | i suspect its water ... not Bitcoin | inanaco |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions